Early Detection of β-Cell Decline Using Home Dried Blood Spot C-Peptide Levels in New-Onset Type 1 Diabetes
Authors' conclusion
Home DBS C-peptide assessment is a feasible method to monitor β-cell function in ND type 1 diabetes. The early prognostic utility of stimulated DBS C-peptide highlights its potential for optimizing trial design. However, further validation is needed to confirm its reliability and broader applicability.
Study context
- Population
- Individuals with newly diagnosed T1D recruited within 6 weeks of diagnosis (INNODIA cohort); mean age 12.7 years, range 1.2–43.8 yearsanalysed
- Participants
- 292 individuals
- Exposure
- Home dried blood spot (DBS) C-peptide vs 12-month mixed-meal tolerance test (MMTT) venous C-peptide
- Outcome
- Prediction of venous MMTT AUC C-peptide by DBS C-peptide slopes
- Follow-up
- 12 months
Methodological detailshome finger-prick DBS sampling, INNODIA cohort
- Home finger-prick DBS sampling
- INNODIA cohort
Main finding
As reported in the abstract
first 6 months
- Slopes of stimulated DBS C-peptide in first 6 months significantly predicted venous MMTT AUC C-peptide and peak C-peptide at 12 months
- P < 0.01
Observational data: associations, not effects.
Further findings
DBS card pairs per participant · over 12 months
- Median number of DBS card pairs per participant (IQR 2, 9)
- 6.5
Original publication
Early Detection of β-Cell Decline Using Home Dried Blood Spot C-Peptide Levels in New-Onset Type 1 Diabetes. Diabetes Care. Published 22 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →